Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
JANX
SellHot AirJanux Therapeutics, Inc. · Healthcare · United States · $1.1B · Avg Vol: $14M/d
COMPANY DESCRIPTION
Janux Therapeutics, Inc. is a clinical-stage biotechnology company developing novel T-cell engager immunotherapies for cancer, utilizing its proprietary Tumour Activated T Cell Engager (TRACTr) platform. The company's innovative TRACTr platform is designed to improve the therapeutic index of T-cell engagers by reducing off-tumor toxicity. It is a niche biopharmaceutical company specializing in next-generation T-cell engager technology for oncology, aiming for safer and more effective cancer treatments.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 8.6M | 8.1M | 10.6M | 10.0M | 5.1% | 24.0M | 29.5M | 8.1M | -10.0% |
| EPS | -1.39 | -1.52 | -1.32 | -1.28 | -1.83 | — | -1.64 | -1.73 | -2.62 | — |
| Shares | — | 41.6M | 46.3M | 59.1M | 60.4M | +45.1% | 61.1M | — | — | — |
| Debt | — | 25.3M | 24.5M | 23.0M | 22.1M | -4.4% | 21.0M | — | — | — |
| Equity | — | 320.7M | 344.3M | 1.0B | 956.8M | 44.0% | — | — | — | — |
| Op CF | — | -42.9M | -50.6M | -43.8M | -82.2M | — | -41.3M | — | — | — |
| Inv CF | — | 58.3M | -41.2M | -258.0M | -301.0M | — | — | — | — | — |
| Fin CF | — | 0.5M | 59.5M | 713.2M | 4.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of JANX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc.(you) | $1.1B | 28 | Sell |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 28 | Sell |
| CADL | Candel Therapeutics, Inc. | $1.0B | 27 | Sell |
| AVTX | Avalo Therapeutics, Inc. | $1.1B | 26 | Sell |
| IMMX | Immix Biopharma, Inc. | $992M | 26 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 29 | Sell |
| KURA | Kura Oncology, Inc. | $1.1B | 23 | Sell |
| APMD | Apnimed, Inc. | $1.2B | 32 | Sell |
| MNKD | MannKind Corporation | $1.3B | 25 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%